Engineering liposomes for drug delivery: progress and problems.
Liposomes were first proposed and tested as a drug delivery system 25 years ago. Since then, advances in our understanding of the fate and behaviour of liposomes at the cellular and subcellular level in vivo have allowed the rational design of constructs for use in the treatment and prevention of disease, both in experimental animals and clinically. The involvement of several liposome-based biotechnology companies in the early 1980s, paralleled by great leaps in liposome technology, has culminated in the design and licencing of formulations for the treatment of certain microbial infections and cancers, and the first liposome-based vaccine for use in humans.
Gregoriadis
G
G
Centre for Drug Delivery Research, School of Pharmacy, University of London, UK.
D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D018796:Immunoconjugates; D008075:Lipoproteins, HDL / Q000627:therapeutic use; D008081:Liposomes / Q000737:chemistry* / Q000276:immunology / Q000627:therapeutic use*; D008247:Lysosomes; D009975:Orthomyxoviridae / Q000737:chemistry / Q000502:physiology; D014612:Vaccines / Q000737:chemistry; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use
D018796:Immunoconjugates; D008075:Lipoproteins, HDL; D008081:Liposomes; D014612:Vaccines; D014759:Viral Envelope Proteins